nodes	percent_of_prediction	percent_of_DWPC	metapath
Naphazoline—Propranolol—Penbutolol—coronary artery disease	0.533	1	CrCrCtD
Naphazoline—Tolazoline—HRH2—coronary artery disease	0.00303	0.538	CrCbGaD
Naphazoline—Lacrimation increased—Enalapril—coronary artery disease	0.00205	0.00814	CcSEcCtD
Naphazoline—Sweating—Penbutolol—coronary artery disease	0.00195	0.00773	CcSEcCtD
Naphazoline—Hypertension—Tirofiban—coronary artery disease	0.00194	0.00768	CcSEcCtD
Naphazoline—Lacrimation increased—Perindopril—coronary artery disease	0.00191	0.00758	CcSEcCtD
Naphazoline—Hyperhidrosis—Tirofiban—coronary artery disease	0.00177	0.00702	CcSEcCtD
Naphazoline—Discomfort—Pitavastatin—coronary artery disease	0.00161	0.00639	CcSEcCtD
Naphazoline—Lacrimation increased—Timolol—coronary artery disease	0.0015	0.00596	CcSEcCtD
Naphazoline—Drowsiness—Acetylsalicylic acid—coronary artery disease	0.00148	0.00588	CcSEcCtD
Naphazoline—Eye disorder—Gemfibrozil—coronary artery disease	0.00146	0.00577	CcSEcCtD
Naphazoline—Eye disorder—Ticagrelor—coronary artery disease	0.00142	0.00564	CcSEcCtD
Naphazoline—Sweating—Acetylsalicylic acid—coronary artery disease	0.00142	0.00564	CcSEcCtD
Naphazoline—Tension—Gemfibrozil—coronary artery disease	0.00133	0.00528	CcSEcCtD
Naphazoline—Nervousness—Gemfibrozil—coronary artery disease	0.00132	0.00522	CcSEcCtD
Naphazoline—Vision blurred—Gemfibrozil—coronary artery disease	0.00128	0.00507	CcSEcCtD
Naphazoline—Sweating—Fenofibrate—coronary artery disease	0.00127	0.00504	CcSEcCtD
Naphazoline—Hyperglycaemia—Eplerenone—coronary artery disease	0.00126	0.00498	CcSEcCtD
Naphazoline—Hyperhidrosis—Penbutolol—coronary artery disease	0.00126	0.00497	CcSEcCtD
Naphazoline—Dizziness—Tirofiban—coronary artery disease	0.00121	0.0048	CcSEcCtD
Naphazoline—Hyperglycaemia—Olmesartan—coronary artery disease	0.00115	0.00456	CcSEcCtD
Naphazoline—Headache—Tirofiban—coronary artery disease	0.00115	0.00455	CcSEcCtD
Naphazoline—Hypertension—Ticagrelor—coronary artery disease	0.00115	0.00454	CcSEcCtD
Naphazoline—Asthenia—Pitavastatin—coronary artery disease	0.00112	0.00445	CcSEcCtD
Naphazoline—Eye pain—Timolol—coronary artery disease	0.00111	0.00441	CcSEcCtD
Naphazoline—Eye disorder—Fenofibrate—coronary artery disease	0.00111	0.00441	CcSEcCtD
Naphazoline—Eye disorder—Clopidogrel—coronary artery disease	0.00109	0.00433	CcSEcCtD
Naphazoline—Nausea—Tirofiban—coronary artery disease	0.00109	0.00431	CcSEcCtD
Naphazoline—Hyperglycaemia—Trandolapril—coronary artery disease	0.00108	0.00426	CcSEcCtD
Naphazoline—Hyperglycaemia—Enalapril—coronary artery disease	0.00107	0.00424	CcSEcCtD
Naphazoline—Sweating—Niacin—coronary artery disease	0.00107	0.00422	CcSEcCtD
Naphazoline—Drowsiness—Trandolapril—coronary artery disease	0.00106	0.00421	CcSEcCtD
Naphazoline—Erythema—Fenofibrate—coronary artery disease	0.00104	0.0041	CcSEcCtD
Naphazoline—Dizziness—Pitavastatin—coronary artery disease	0.00103	0.0041	CcSEcCtD
Naphazoline—Sweating—Trandolapril—coronary artery disease	0.00102	0.00404	CcSEcCtD
Naphazoline—Tension—Fenofibrate—coronary artery disease	0.00102	0.00403	CcSEcCtD
Naphazoline—Nervousness—Fenofibrate—coronary artery disease	0.00101	0.00399	CcSEcCtD
Naphazoline—Hypertension—Acetylsalicylic acid—coronary artery disease	0.001	0.00397	CcSEcCtD
Naphazoline—Erythema—Ezetimibe—coronary artery disease	0.000992	0.00393	CcSEcCtD
Naphazoline—Drowsiness—Perindopril—coronary artery disease	0.000986	0.00391	CcSEcCtD
Naphazoline—Somnolence—Gemfibrozil—coronary artery disease	0.000985	0.0039	CcSEcCtD
Naphazoline—Headache—Pitavastatin—coronary artery disease	0.00098	0.00388	CcSEcCtD
Naphazoline—Hyperglycaemia—Furosemide—coronary artery disease	0.00097	0.00384	CcSEcCtD
Naphazoline—Drowsiness—Furosemide—coronary artery disease	0.000959	0.0038	CcSEcCtD
Naphazoline—Vision blurred—Lovastatin—coronary artery disease	0.000953	0.00378	CcSEcCtD
Naphazoline—Erythema—Simvastatin—coronary artery disease	0.000946	0.00375	CcSEcCtD
Naphazoline—Sweating—Perindopril—coronary artery disease	0.000945	0.00374	CcSEcCtD
Naphazoline—Hyperglycaemia—Losartan—coronary artery disease	0.000936	0.00371	CcSEcCtD
Naphazoline—Eye disorder—Niacin—coronary artery disease	0.000933	0.0037	CcSEcCtD
Naphazoline—Asthenia—Penbutolol—coronary artery disease	0.000932	0.00369	CcSEcCtD
Naphazoline—Nausea—Pitavastatin—coronary artery disease	0.000929	0.00368	CcSEcCtD
Naphazoline—Sweating—Furosemide—coronary artery disease	0.000919	0.00364	CcSEcCtD
Naphazoline—Hyperhidrosis—Acetylsalicylic acid—coronary artery disease	0.000915	0.00362	CcSEcCtD
Naphazoline—Hypertension—Fenofibrate—coronary artery disease	0.000895	0.00354	CcSEcCtD
Naphazoline—Eye disorder—Trandolapril—coronary artery disease	0.000892	0.00353	CcSEcCtD
Naphazoline—Vision blurred—Simvastatin—coronary artery disease	0.000892	0.00353	CcSEcCtD
Naphazoline—Sweating—Losartan—coronary artery disease	0.000887	0.00351	CcSEcCtD
Naphazoline—Terbinafine—CYP2C19—coronary artery disease	0.000883	0.157	CrCbGaD
Naphazoline—Hypertension—Clopidogrel—coronary artery disease	0.000879	0.00348	CcSEcCtD
Naphazoline—Eye disorder—Telmisartan—coronary artery disease	0.000876	0.00347	CcSEcCtD
Naphazoline—Discomfort—Fenofibrate—coronary artery disease	0.000872	0.00345	CcSEcCtD
Naphazoline—Erythema—Niacin—coronary artery disease	0.000869	0.00344	CcSEcCtD
Naphazoline—Dizziness—Penbutolol—coronary artery disease	0.000859	0.0034	CcSEcCtD
Naphazoline—Hypertension—Ezetimibe—coronary artery disease	0.000857	0.00339	CcSEcCtD
Naphazoline—Tension—Niacin—coronary artery disease	0.000853	0.00338	CcSEcCtD
Naphazoline—Discomfort—Lovastatin—coronary artery disease	0.000851	0.00337	CcSEcCtD
Naphazoline—Nervousness—Niacin—coronary artery disease	0.000844	0.00334	CcSEcCtD
Naphazoline—Vision blurred—Valsartan—coronary artery disease	0.000842	0.00334	CcSEcCtD
Naphazoline—Somnolence—Acetylsalicylic acid—coronary artery disease	0.000841	0.00333	CcSEcCtD
Naphazoline—Tension—Pravastatin—coronary artery disease	0.00084	0.00333	CcSEcCtD
Naphazoline—Vision blurred—Olmesartan—coronary artery disease	0.000838	0.00332	CcSEcCtD
Naphazoline—Discomfort—Ezetimibe—coronary artery disease	0.000835	0.00331	CcSEcCtD
Naphazoline—Nervousness—Pravastatin—coronary artery disease	0.000831	0.00329	CcSEcCtD
Naphazoline—Erythema—Enalapril—coronary artery disease	0.000827	0.00328	CcSEcCtD
Naphazoline—Eye disorder—Perindopril—coronary artery disease	0.000827	0.00328	CcSEcCtD
Naphazoline—Vision blurred—Niacin—coronary artery disease	0.000819	0.00324	CcSEcCtD
Naphazoline—Hyperhidrosis—Fenofibrate—coronary artery disease	0.000817	0.00324	CcSEcCtD
Naphazoline—Discomfort—Eplerenone—coronary artery disease	0.000817	0.00324	CcSEcCtD
Naphazoline—Erythema—Telmisartan—coronary artery disease	0.000816	0.00323	CcSEcCtD
Naphazoline—Headache—Penbutolol—coronary artery disease	0.000814	0.00322	CcSEcCtD
Naphazoline—Tension—Enalapril—coronary artery disease	0.000812	0.00322	CcSEcCtD
Naphazoline—Vision blurred—Pravastatin—coronary artery disease	0.000806	0.00319	CcSEcCtD
Naphazoline—Eye disorder—Furosemide—coronary artery disease	0.000804	0.00319	CcSEcCtD
Naphazoline—Nervousness—Enalapril—coronary artery disease	0.000804	0.00318	CcSEcCtD
Naphazoline—Tension—Telmisartan—coronary artery disease	0.000801	0.00317	CcSEcCtD
Naphazoline—Discomfort—Simvastatin—coronary artery disease	0.000796	0.00315	CcSEcCtD
Naphazoline—Asthenia—Gemfibrozil—coronary artery disease	0.000795	0.00315	CcSEcCtD
Naphazoline—Nervousness—Telmisartan—coronary artery disease	0.000793	0.00314	CcSEcCtD
Naphazoline—Hyperglycaemia—Timolol—coronary artery disease	0.000784	0.00311	CcSEcCtD
Naphazoline—Vision blurred—Enalapril—coronary artery disease	0.00078	0.00309	CcSEcCtD
Naphazoline—Tension—Captopril—coronary artery disease	0.000779	0.00309	CcSEcCtD
Naphazoline—Asthenia—Ticagrelor—coronary artery disease	0.000777	0.00308	CcSEcCtD
Naphazoline—Nausea—Penbutolol—coronary artery disease	0.000771	0.00306	CcSEcCtD
Naphazoline—Nervousness—Captopril—coronary artery disease	0.000771	0.00305	CcSEcCtD
Naphazoline—Erythema—Perindopril—coronary artery disease	0.000771	0.00305	CcSEcCtD
Naphazoline—Hyperhidrosis—Eplerenone—coronary artery disease	0.000766	0.00304	CcSEcCtD
Naphazoline—Sweating—Ramipril—coronary artery disease	0.00076	0.00301	CcSEcCtD
Naphazoline—Tension—Perindopril—coronary artery disease	0.000756	0.003	CcSEcCtD
Naphazoline—Somnolence—Fenofibrate—coronary artery disease	0.000752	0.00298	CcSEcCtD
Naphazoline—Erythema—Furosemide—coronary artery disease	0.000749	0.00297	CcSEcCtD
Naphazoline—Nervousness—Perindopril—coronary artery disease	0.000748	0.00296	CcSEcCtD
Naphazoline—Discomfort—Olmesartan—coronary artery disease	0.000748	0.00296	CcSEcCtD
Naphazoline—Vision blurred—Captopril—coronary artery disease	0.000748	0.00296	CcSEcCtD
Naphazoline—Sweating—Timolol—coronary artery disease	0.000743	0.00294	CcSEcCtD
Naphazoline—Hypertension—Pravastatin—coronary artery disease	0.000739	0.00293	CcSEcCtD
Naphazoline—Dizziness—Gemfibrozil—coronary artery disease	0.000733	0.0029	CcSEcCtD
Naphazoline—Hyperglycaemia—Lisinopril—coronary artery disease	0.000728	0.00288	CcSEcCtD
Naphazoline—Erythema—Losartan—coronary artery disease	0.000723	0.00286	CcSEcCtD
Naphazoline—Discomfort—Pravastatin—coronary artery disease	0.00072	0.00285	CcSEcCtD
Naphazoline—Dizziness—Ticagrelor—coronary artery disease	0.000716	0.00284	CcSEcCtD
Naphazoline—Tension—Losartan—coronary artery disease	0.000709	0.00281	CcSEcCtD
Naphazoline—Vision blurred—Furosemide—coronary artery disease	0.000706	0.0028	CcSEcCtD
Naphazoline—Hypertension—Telmisartan—coronary artery disease	0.000705	0.00279	CcSEcCtD
Naphazoline—Nervousness—Losartan—coronary artery disease	0.000702	0.00278	CcSEcCtD
Naphazoline—Hyperhidrosis—Olmesartan—coronary artery disease	0.000702	0.00278	CcSEcCtD
Naphazoline—Asthenia—Rosuvastatin—coronary artery disease	0.000699	0.00277	CcSEcCtD
Naphazoline—Discomfort—Trandolapril—coronary artery disease	0.000699	0.00277	CcSEcCtD
Naphazoline—Discomfort—Enalapril—coronary artery disease	0.000696	0.00276	CcSEcCtD
Naphazoline—Headache—Gemfibrozil—coronary artery disease	0.000694	0.00275	CcSEcCtD
Naphazoline—Sweating—Lisinopril—coronary artery disease	0.00069	0.00273	CcSEcCtD
Naphazoline—Discomfort—Telmisartan—coronary artery disease	0.000687	0.00272	CcSEcCtD
Naphazoline—Hyperhidrosis—Niacin—coronary artery disease	0.000686	0.00272	CcSEcCtD
Naphazoline—Vision blurred—Losartan—coronary artery disease	0.000681	0.0027	CcSEcCtD
Naphazoline—Headache—Ticagrelor—coronary artery disease	0.000678	0.00269	CcSEcCtD
Naphazoline—Hyperhidrosis—Pravastatin—coronary artery disease	0.000675	0.00267	CcSEcCtD
Naphazoline—Discomfort—Captopril—coronary artery disease	0.000668	0.00264	CcSEcCtD
Naphazoline—Hypertension—Perindopril—coronary artery disease	0.000665	0.00264	CcSEcCtD
Naphazoline—Nausea—Gemfibrozil—coronary artery disease	0.000658	0.00261	CcSEcCtD
Naphazoline—Hyperhidrosis—Trandolapril—coronary artery disease	0.000655	0.0026	CcSEcCtD
Naphazoline—Hyperhidrosis—Enalapril—coronary artery disease	0.000653	0.00259	CcSEcCtD
Naphazoline—Eye disorder—Timolol—coronary artery disease	0.00065	0.00258	CcSEcCtD
Naphazoline—Somnolence—Valsartan—coronary artery disease	0.000648	0.00257	CcSEcCtD
Naphazoline—Discomfort—Perindopril—coronary artery disease	0.000648	0.00257	CcSEcCtD
Naphazoline—Dizziness—Rosuvastatin—coronary artery disease	0.000644	0.00255	CcSEcCtD
Naphazoline—Hyperhidrosis—Telmisartan—coronary artery disease	0.000644	0.00255	CcSEcCtD
Naphazoline—Nausea—Ticagrelor—coronary artery disease	0.000643	0.00255	CcSEcCtD
Naphazoline—Somnolence—Niacin—coronary artery disease	0.00063	0.0025	CcSEcCtD
Naphazoline—Dizziness—Acetylsalicylic acid—coronary artery disease	0.000626	0.00248	CcSEcCtD
Naphazoline—Erythema—Ramipril—coronary artery disease	0.00062	0.00246	CcSEcCtD
Naphazoline—Headache—Rosuvastatin—coronary artery disease	0.00061	0.00242	CcSEcCtD
Naphazoline—Tension—Ramipril—coronary artery disease	0.000608	0.00241	CcSEcCtD
Naphazoline—Hyperhidrosis—Perindopril—coronary artery disease	0.000608	0.00241	CcSEcCtD
Naphazoline—Discomfort—Losartan—coronary artery disease	0.000608	0.00241	CcSEcCtD
Naphazoline—Asthenia—Fenofibrate—coronary artery disease	0.000607	0.0024	CcSEcCtD
Naphazoline—Erythema—Timolol—coronary artery disease	0.000606	0.0024	CcSEcCtD
Naphazoline—Somnolence—Trandolapril—coronary artery disease	0.000603	0.00239	CcSEcCtD
Naphazoline—Nervousness—Ramipril—coronary artery disease	0.000602	0.00238	CcSEcCtD
Naphazoline—Somnolence—Enalapril—coronary artery disease	0.0006	0.00238	CcSEcCtD
Naphazoline—Asthenia—Clopidogrel—coronary artery disease	0.000596	0.00236	CcSEcCtD
Naphazoline—Tension—Timolol—coronary artery disease	0.000595	0.00236	CcSEcCtD
Naphazoline—Asthenia—Lovastatin—coronary artery disease	0.000592	0.00235	CcSEcCtD
Naphazoline—Somnolence—Telmisartan—coronary artery disease	0.000592	0.00235	CcSEcCtD
Naphazoline—Hyperhidrosis—Furosemide—coronary artery disease	0.000591	0.00234	CcSEcCtD
Naphazoline—Nervousness—Timolol—coronary artery disease	0.000588	0.00233	CcSEcCtD
Naphazoline—Asthenia—Ezetimibe—coronary artery disease	0.000581	0.0023	CcSEcCtD
Naphazoline—Nausea—Rosuvastatin—coronary artery disease	0.000579	0.00229	CcSEcCtD
Naphazoline—Somnolence—Captopril—coronary artery disease	0.000576	0.00228	CcSEcCtD
Naphazoline—Vision blurred—Timolol—coronary artery disease	0.000571	0.00226	CcSEcCtD
Naphazoline—Hyperhidrosis—Losartan—coronary artery disease	0.00057	0.00226	CcSEcCtD
Naphazoline—Asthenia—Eplerenone—coronary artery disease	0.000569	0.00225	CcSEcCtD
Naphazoline—Nausea—Acetylsalicylic acid—coronary artery disease	0.000562	0.00223	CcSEcCtD
Naphazoline—Erythema—Lisinopril—coronary artery disease	0.000562	0.00223	CcSEcCtD
Naphazoline—Dizziness—Fenofibrate—coronary artery disease	0.000559	0.00222	CcSEcCtD
Naphazoline—Somnolence—Perindopril—coronary artery disease	0.000559	0.00221	CcSEcCtD
Naphazoline—Asthenia—Simvastatin—coronary artery disease	0.000554	0.0022	CcSEcCtD
Naphazoline—Tension—Lisinopril—coronary artery disease	0.000552	0.00218	CcSEcCtD
Naphazoline—Dizziness—Clopidogrel—coronary artery disease	0.00055	0.00218	CcSEcCtD
Naphazoline—Dizziness—Lovastatin—coronary artery disease	0.000546	0.00216	CcSEcCtD
Naphazoline—Nervousness—Lisinopril—coronary artery disease	0.000546	0.00216	CcSEcCtD
Naphazoline—Somnolence—Furosemide—coronary artery disease	0.000543	0.00215	CcSEcCtD
Naphazoline—Duloxetine—HTR2A—coronary artery disease	0.00054	0.096	CrCbGaD
Naphazoline—Dizziness—Ezetimibe—coronary artery disease	0.000536	0.00212	CcSEcCtD
Naphazoline—Headache—Fenofibrate—coronary artery disease	0.00053	0.0021	CcSEcCtD
Naphazoline—Vision blurred—Lisinopril—coronary artery disease	0.00053	0.0021	CcSEcCtD
Naphazoline—Somnolence—Losartan—coronary artery disease	0.000524	0.00208	CcSEcCtD
Naphazoline—Dizziness—Eplerenone—coronary artery disease	0.000524	0.00208	CcSEcCtD
Naphazoline—Asthenia—Valsartan—coronary artery disease	0.000523	0.00207	CcSEcCtD
Naphazoline—Hypertension—Timolol—coronary artery disease	0.000523	0.00207	CcSEcCtD
Naphazoline—Discomfort—Ramipril—coronary artery disease	0.000521	0.00207	CcSEcCtD
Naphazoline—Asthenia—Olmesartan—coronary artery disease	0.000521	0.00206	CcSEcCtD
Naphazoline—Headache—Clopidogrel—coronary artery disease	0.000521	0.00206	CcSEcCtD
Naphazoline—Headache—Lovastatin—coronary artery disease	0.000517	0.00205	CcSEcCtD
Naphazoline—Dizziness—Simvastatin—coronary artery disease	0.000511	0.00202	CcSEcCtD
Naphazoline—Discomfort—Timolol—coronary artery disease	0.00051	0.00202	CcSEcCtD
Naphazoline—Asthenia—Niacin—coronary artery disease	0.000509	0.00202	CcSEcCtD
Naphazoline—Headache—Ezetimibe—coronary artery disease	0.000507	0.00201	CcSEcCtD
Naphazoline—Nausea—Fenofibrate—coronary artery disease	0.000502	0.00199	CcSEcCtD
Naphazoline—Asthenia—Pravastatin—coronary artery disease	0.000501	0.00198	CcSEcCtD
Naphazoline—Headache—Eplerenone—coronary artery disease	0.000497	0.00197	CcSEcCtD
Naphazoline—Nausea—Clopidogrel—coronary artery disease	0.000494	0.00196	CcSEcCtD
Naphazoline—Nausea—Lovastatin—coronary artery disease	0.00049	0.00194	CcSEcCtD
Naphazoline—Hyperhidrosis—Ramipril—coronary artery disease	0.000489	0.00194	CcSEcCtD
Naphazoline—Asthenia—Trandolapril—coronary artery disease	0.000486	0.00193	CcSEcCtD
Naphazoline—Asthenia—Enalapril—coronary artery disease	0.000485	0.00192	CcSEcCtD
Naphazoline—Headache—Simvastatin—coronary artery disease	0.000484	0.00192	CcSEcCtD
Naphazoline—Dizziness—Valsartan—coronary artery disease	0.000482	0.00191	CcSEcCtD
Naphazoline—Nausea—Ezetimibe—coronary artery disease	0.000481	0.00191	CcSEcCtD
Naphazoline—Dizziness—Olmesartan—coronary artery disease	0.00048	0.0019	CcSEcCtD
Naphazoline—Hyperhidrosis—Timolol—coronary artery disease	0.000478	0.00189	CcSEcCtD
Naphazoline—Asthenia—Telmisartan—coronary artery disease	0.000478	0.00189	CcSEcCtD
Naphazoline—Discomfort—Lisinopril—coronary artery disease	0.000473	0.00187	CcSEcCtD
Naphazoline—Nausea—Eplerenone—coronary artery disease	0.000471	0.00187	CcSEcCtD
Naphazoline—Dizziness—Niacin—coronary artery disease	0.000469	0.00186	CcSEcCtD
Naphazoline—Asthenia—Captopril—coronary artery disease	0.000465	0.00184	CcSEcCtD
Naphazoline—Dizziness—Pravastatin—coronary artery disease	0.000462	0.00183	CcSEcCtD
Naphazoline—Nausea—Simvastatin—coronary artery disease	0.000459	0.00182	CcSEcCtD
Naphazoline—Propranolol—ADRB1—coronary artery disease	0.000458	0.0814	CrCbGaD
Naphazoline—Headache—Valsartan—coronary artery disease	0.000457	0.00181	CcSEcCtD
Naphazoline—Headache—Olmesartan—coronary artery disease	0.000455	0.0018	CcSEcCtD
Naphazoline—Asthenia—Perindopril—coronary artery disease	0.000451	0.00179	CcSEcCtD
Naphazoline—Somnolence—Ramipril—coronary artery disease	0.00045	0.00178	CcSEcCtD
Naphazoline—Dizziness—Trandolapril—coronary artery disease	0.000448	0.00178	CcSEcCtD
Naphazoline—Dizziness—Enalapril—coronary artery disease	0.000447	0.00177	CcSEcCtD
Naphazoline—Headache—Niacin—coronary artery disease	0.000444	0.00176	CcSEcCtD
Naphazoline—Hyperhidrosis—Lisinopril—coronary artery disease	0.000443	0.00176	CcSEcCtD
Naphazoline—Dizziness—Telmisartan—coronary artery disease	0.00044	0.00174	CcSEcCtD
Naphazoline—Somnolence—Timolol—coronary artery disease	0.00044	0.00174	CcSEcCtD
Naphazoline—Asthenia—Furosemide—coronary artery disease	0.000439	0.00174	CcSEcCtD
Naphazoline—Headache—Pravastatin—coronary artery disease	0.000437	0.00173	CcSEcCtD
Naphazoline—Nausea—Valsartan—coronary artery disease	0.000433	0.00172	CcSEcCtD
Naphazoline—Nausea—Olmesartan—coronary artery disease	0.000431	0.00171	CcSEcCtD
Naphazoline—Dizziness—Captopril—coronary artery disease	0.000428	0.0017	CcSEcCtD
Naphazoline—Headache—Trandolapril—coronary artery disease	0.000425	0.00168	CcSEcCtD
Naphazoline—Asthenia—Losartan—coronary artery disease	0.000423	0.00168	CcSEcCtD
Naphazoline—Headache—Enalapril—coronary artery disease	0.000423	0.00168	CcSEcCtD
Naphazoline—Nausea—Niacin—coronary artery disease	0.000421	0.00167	CcSEcCtD
Naphazoline—Headache—Telmisartan—coronary artery disease	0.000417	0.00165	CcSEcCtD
Naphazoline—Dizziness—Perindopril—coronary artery disease	0.000416	0.00165	CcSEcCtD
Naphazoline—Nausea—Pravastatin—coronary artery disease	0.000415	0.00164	CcSEcCtD
Naphazoline—Somnolence—Lisinopril—coronary artery disease	0.000408	0.00162	CcSEcCtD
Naphazoline—Headache—Captopril—coronary artery disease	0.000406	0.00161	CcSEcCtD
Naphazoline—Dizziness—Furosemide—coronary artery disease	0.000404	0.0016	CcSEcCtD
Naphazoline—Nausea—Trandolapril—coronary artery disease	0.000403	0.0016	CcSEcCtD
Naphazoline—Nausea—Enalapril—coronary artery disease	0.000401	0.00159	CcSEcCtD
Naphazoline—Nausea—Telmisartan—coronary artery disease	0.000396	0.00157	CcSEcCtD
Naphazoline—Headache—Perindopril—coronary artery disease	0.000394	0.00156	CcSEcCtD
Naphazoline—Dizziness—Losartan—coronary artery disease	0.00039	0.00155	CcSEcCtD
Naphazoline—Propranolol—ADRB2—coronary artery disease	0.000385	0.0684	CrCbGaD
Naphazoline—Nausea—Captopril—coronary artery disease	0.000385	0.00152	CcSEcCtD
Naphazoline—Headache—Furosemide—coronary artery disease	0.000383	0.00152	CcSEcCtD
Naphazoline—Nausea—Perindopril—coronary artery disease	0.000374	0.00148	CcSEcCtD
Naphazoline—Headache—Losartan—coronary artery disease	0.00037	0.00146	CcSEcCtD
Naphazoline—Nausea—Furosemide—coronary artery disease	0.000363	0.00144	CcSEcCtD
Naphazoline—Asthenia—Ramipril—coronary artery disease	0.000363	0.00144	CcSEcCtD
Naphazoline—Asthenia—Timolol—coronary artery disease	0.000355	0.00141	CcSEcCtD
Naphazoline—Nausea—Losartan—coronary artery disease	0.00035	0.00139	CcSEcCtD
Naphazoline—Dizziness—Ramipril—coronary artery disease	0.000334	0.00132	CcSEcCtD
Naphazoline—Propranolol—CYP2C19—coronary artery disease	0.000331	0.0589	CrCbGaD
Naphazoline—Asthenia—Lisinopril—coronary artery disease	0.000329	0.0013	CcSEcCtD
Naphazoline—Dizziness—Timolol—coronary artery disease	0.000327	0.0013	CcSEcCtD
Naphazoline—Headache—Ramipril—coronary artery disease	0.000317	0.00126	CcSEcCtD
Naphazoline—Headache—Timolol—coronary artery disease	0.00031	0.00123	CcSEcCtD
Naphazoline—Dizziness—Lisinopril—coronary artery disease	0.000303	0.0012	CcSEcCtD
Naphazoline—Nausea—Ramipril—coronary artery disease	0.0003	0.00119	CcSEcCtD
Naphazoline—Nausea—Timolol—coronary artery disease	0.000294	0.00116	CcSEcCtD
Naphazoline—Headache—Lisinopril—coronary artery disease	0.000287	0.00114	CcSEcCtD
Naphazoline—Nausea—Lisinopril—coronary artery disease	0.000272	0.00108	CcSEcCtD
Naphazoline—ADRA2C—Signaling Pathways—RPS6KB1—coronary artery disease	1.55e-05	7.44e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—APOA1—coronary artery disease	1.55e-05	7.44e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—S100B—coronary artery disease	1.55e-05	7.44e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—CREB1—coronary artery disease	1.55e-05	7.43e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—POMC—coronary artery disease	1.55e-05	7.43e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—GSTM1—coronary artery disease	1.55e-05	7.43e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—AGTR1—coronary artery disease	1.55e-05	7.41e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PRKCD—coronary artery disease	1.55e-05	7.4e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—SOCS3—coronary artery disease	1.54e-05	7.36e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Hemostasis—MAPK1—coronary artery disease	1.53e-05	7.32e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—LPL—coronary artery disease	1.52e-05	7.29e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—KITLG—coronary artery disease	1.52e-05	7.28e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—TGFBR2—coronary artery disease	1.52e-05	7.28e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—CCL2—coronary artery disease	1.52e-05	7.27e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—IL6R—coronary artery disease	1.51e-05	7.25e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—ITGB3—coronary artery disease	1.51e-05	7.25e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—HTR2A—coronary artery disease	1.51e-05	7.25e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CXCL10—coronary artery disease	1.51e-05	7.24e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—C3—coronary artery disease	1.51e-05	7.24e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PLG—coronary artery disease	1.51e-05	7.22e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—GPX1—coronary artery disease	1.48e-05	7.11e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MMP3—coronary artery disease	1.48e-05	7.11e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—STAT5A—coronary artery disease	1.48e-05	7.11e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—CXCL8—coronary artery disease	1.48e-05	7.08e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PPP2CA—coronary artery disease	1.47e-05	7.04e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—ADRB2—coronary artery disease	1.47e-05	7.03e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PRKCE—coronary artery disease	1.45e-05	6.94e-05	CbGpPWpGaD
Naphazoline—ADRA2A—GPCR downstream signaling—JAK2—coronary artery disease	1.45e-05	6.94e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—CD36—coronary artery disease	1.45e-05	6.93e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—SOCS1—coronary artery disease	1.45e-05	6.93e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PRKCD—coronary artery disease	1.44e-05	6.92e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—S100B—coronary artery disease	1.44e-05	6.91e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—HIF1A—coronary artery disease	1.44e-05	6.9e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—AGT—coronary artery disease	1.44e-05	6.88e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—APOB—coronary artery disease	1.43e-05	6.87e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Hemostasis—AKT1—coronary artery disease	1.43e-05	6.84e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PPP2CA—coronary artery disease	1.43e-05	6.84e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—SOCS3—coronary artery disease	1.43e-05	6.84e-05	CbGpPWpGaD
Naphazoline—ADRA1A—GPCR downstream signaling—CXCL8—coronary artery disease	1.42e-05	6.81e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—JAK2—coronary artery disease	1.42e-05	6.78e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—HTR2A—coronary artery disease	1.41e-05	6.77e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—EDN1—coronary artery disease	1.41e-05	6.76e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—KITLG—coronary artery disease	1.41e-05	6.76e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—TGFBR2—coronary artery disease	1.41e-05	6.76e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—C3—coronary artery disease	1.41e-05	6.76e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—LEP—coronary artery disease	1.41e-05	6.74e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—APOE—coronary artery disease	1.41e-05	6.74e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CCL5—coronary artery disease	1.4e-05	6.71e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—APOA1—coronary artery disease	1.39e-05	6.66e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—FGF1—coronary artery disease	1.38e-05	6.61e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CSF2—coronary artery disease	1.38e-05	6.61e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—STAT5A—coronary artery disease	1.38e-05	6.61e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MMP3—coronary artery disease	1.38e-05	6.61e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—KDR—coronary artery disease	1.38e-05	6.6e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—MTHFR—coronary artery disease	1.37e-05	6.57e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—LPL—coronary artery disease	1.37e-05	6.56e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MAPK14—coronary artery disease	1.37e-05	6.56e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PPARG—coronary artery disease	1.37e-05	6.55e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—RPS6KB1—coronary artery disease	1.36e-05	6.5e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MEF2C—coronary artery disease	1.36e-05	6.5e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—POMC—coronary artery disease	1.35e-05	6.46e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—HIF1A—coronary artery disease	1.35e-05	6.45e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—ESR1—coronary artery disease	1.34e-05	6.43e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—AGT—coronary artery disease	1.34e-05	6.42e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Hemostasis—AKT1—coronary artery disease	1.33e-05	6.39e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—APOB—coronary artery disease	1.33e-05	6.39e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Hemostasis—PIK3CA—coronary artery disease	1.33e-05	6.36e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—FN1—coronary artery disease	1.33e-05	6.35e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—F2—coronary artery disease	1.33e-05	6.35e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—ITGB3—coronary artery disease	1.32e-05	6.34e-05	CbGpPWpGaD
Naphazoline—ADRA2A—GPCR downstream signaling—CXCL8—coronary artery disease	1.32e-05	6.33e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—IL6ST—coronary artery disease	1.32e-05	6.33e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—JAK2—coronary artery disease	1.31e-05	6.3e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—LEP—coronary artery disease	1.31e-05	6.29e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—APOE—coronary artery disease	1.31e-05	6.29e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—EDN1—coronary artery disease	1.31e-05	6.28e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—NFKBIA—coronary artery disease	1.31e-05	6.28e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—AGT—coronary artery disease	1.3e-05	6.24e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CCL5—coronary artery disease	1.3e-05	6.24e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—APOA1—coronary artery disease	1.3e-05	6.22e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—CXCL8—coronary artery disease	1.29e-05	6.19e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—KDR—coronary artery disease	1.29e-05	6.16e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PPP2CA—coronary artery disease	1.29e-05	6.16e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CSF2—coronary artery disease	1.28e-05	6.14e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—FGF1—coronary artery disease	1.28e-05	6.14e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MAPK14—coronary artery disease	1.28e-05	6.12e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—APOE—coronary artery disease	1.28e-05	6.11e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—LPL—coronary artery disease	1.27e-05	6.1e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—KIT—coronary artery disease	1.27e-05	6.08e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PRKCD—coronary artery disease	1.26e-05	6.05e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—RPS6KB1—coronary artery disease	1.26e-05	6.04e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MEF2C—coronary artery disease	1.26e-05	6.04e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—APOA1—coronary artery disease	1.26e-05	6.04e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—ESR1—coronary artery disease	1.25e-05	6.01e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—FN1—coronary artery disease	1.24e-05	5.93e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—F2—coronary artery disease	1.24e-05	5.93e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—HTR2A—coronary artery disease	1.24e-05	5.92e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—IL6ST—coronary artery disease	1.23e-05	5.91e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—C3—coronary artery disease	1.23e-05	5.91e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—ALB—coronary artery disease	1.23e-05	5.89e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—ITGB3—coronary artery disease	1.23e-05	5.89e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—NFKBIA—coronary artery disease	1.22e-05	5.86e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—GSK3B—coronary artery disease	1.22e-05	5.83e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—POMC—coronary artery disease	1.21e-05	5.79e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CREB1—coronary artery disease	1.21e-05	5.79e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—CXCL8—coronary artery disease	1.2e-05	5.75e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PPP2CA—coronary artery disease	1.19e-05	5.72e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—KIT—coronary artery disease	1.19e-05	5.68e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CCL2—coronary artery disease	1.18e-05	5.66e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—IL6R—coronary artery disease	1.18e-05	5.65e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—NOS3—coronary artery disease	1.18e-05	5.64e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—HIF1A—coronary artery disease	1.18e-05	5.64e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PRKCD—coronary artery disease	1.17e-05	5.62e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—AGT—coronary artery disease	1.17e-05	5.61e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—IGF1—coronary artery disease	1.16e-05	5.57e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—MAPK1—coronary artery disease	1.16e-05	5.54e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—LEP—coronary artery disease	1.15e-05	5.5e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—APOE—coronary artery disease	1.15e-05	5.5e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—HTR2A—coronary artery disease	1.15e-05	5.5e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—C3—coronary artery disease	1.15e-05	5.49e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—GSK3B—coronary artery disease	1.14e-05	5.45e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—APOA1—coronary artery disease	1.14e-05	5.44e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CREB1—coronary artery disease	1.13e-05	5.41e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—POMC—coronary artery disease	1.13e-05	5.41e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—KDR—coronary artery disease	1.12e-05	5.39e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MAPK14—coronary artery disease	1.12e-05	5.35e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PPARG—coronary artery disease	1.11e-05	5.32e-05	CbGpPWpGaD
Naphazoline—ADRA2B—GPCR downstream signaling—PIK3CA—coronary artery disease	1.1e-05	5.29e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CCL2—coronary artery disease	1.1e-05	5.29e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—SERPINE1—coronary artery disease	1.1e-05	5.29e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—IL6R—coronary artery disease	1.1e-05	5.27e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—ESR1—coronary artery disease	1.1e-05	5.25e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—POMC—coronary artery disease	1.1e-05	5.25e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—HIF1A—coronary artery disease	1.09e-05	5.24e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—AGT—coronary artery disease	1.09e-05	5.22e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—IGF1—coronary artery disease	1.09e-05	5.2e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Hemostasis—AKT1—coronary artery disease	1.08e-05	5.19e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—F2—coronary artery disease	1.08e-05	5.19e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—FN1—coronary artery disease	1.08e-05	5.19e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—MAPK1—coronary artery disease	1.08e-05	5.17e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IL6ST—coronary artery disease	1.08e-05	5.17e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PTGS2—coronary artery disease	1.08e-05	5.16e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—NFKBIA—coronary artery disease	1.07e-05	5.13e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—FGF2—coronary artery disease	1.07e-05	5.12e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—LEP—coronary artery disease	1.07e-05	5.11e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—APOE—coronary artery disease	1.07e-05	5.11e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—APOA1—coronary artery disease	1.05e-05	5.05e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—NOS3—coronary artery disease	1.05e-05	5.05e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—KDR—coronary artery disease	1.05e-05	5.01e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MAPK14—coronary artery disease	1.04e-05	4.97e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—KIT—coronary artery disease	1.04e-05	4.96e-05	CbGpPWpGaD
Naphazoline—ADRA2C—GPCR downstream signaling—PIK3CA—coronary artery disease	1.03e-05	4.94e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—SERPINE1—coronary artery disease	1.03e-05	4.94e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—JAK2—coronary artery disease	1.02e-05	4.9e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—ESR1—coronary artery disease	1.02e-05	4.88e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—F2—coronary artery disease	1.01e-05	4.82e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—FN1—coronary artery disease	1.01e-05	4.82e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—PIK3CA—coronary artery disease	1e-05	4.81e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IL6ST—coronary artery disease	1e-05	4.8e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—ALB—coronary artery disease	9.99e-06	4.79e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—FGF2—coronary artery disease	9.98e-06	4.78e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—GSK3B—coronary artery disease	9.94e-06	4.76e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—NFKBIA—coronary artery disease	9.94e-06	4.76e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—POMC—coronary artery disease	9.86e-06	4.73e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CREB1—coronary artery disease	9.86e-06	4.73e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—NOS3—coronary artery disease	9.84e-06	4.71e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CCL2—coronary artery disease	9.65e-06	4.62e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—KIT—coronary artery disease	9.63e-06	4.61e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IL6R—coronary artery disease	9.62e-06	4.61e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—JAK2—coronary artery disease	9.56e-06	4.58e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—NOS3—coronary artery disease	9.56e-06	4.58e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IGF1—coronary artery disease	9.49e-06	4.55e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—MAPK1—coronary artery disease	9.44e-06	4.52e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—PIK3CA—coronary artery disease	9.37e-06	4.49e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CXCL8—coronary artery disease	9.34e-06	4.48e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—GSK3B—coronary artery disease	9.24e-06	4.43e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—POMC—coronary artery disease	9.16e-06	4.39e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CREB1—coronary artery disease	9.16e-06	4.39e-05	CbGpPWpGaD
Naphazoline—ADRA2B—GPCR downstream signaling—AKT1—coronary artery disease	9.03e-06	4.32e-05	CbGpPWpGaD
Naphazoline—ADRA1A—GPCR downstream signaling—PIK3CA—coronary artery disease	9.02e-06	4.32e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—SERPINE1—coronary artery disease	9.01e-06	4.32e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CCL2—coronary artery disease	8.97e-06	4.3e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CASP3—coronary artery disease	8.94e-06	4.28e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IL6R—coronary artery disease	8.94e-06	4.28e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—IL6—coronary artery disease	8.89e-06	4.26e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IGF1—coronary artery disease	8.82e-06	4.22e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—MAPK1—coronary artery disease	8.77e-06	4.2e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PTGS2—coronary artery disease	8.74e-06	4.19e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CXCL8—coronary artery disease	8.73e-06	4.18e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—FGF2—coronary artery disease	8.72e-06	4.18e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CCND1—coronary artery disease	8.71e-06	4.17e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—NOS3—coronary artery disease	8.6e-06	4.12e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MMP9—coronary artery disease	8.45e-06	4.05e-05	CbGpPWpGaD
Naphazoline—ADRA2C—GPCR downstream signaling—AKT1—coronary artery disease	8.43e-06	4.04e-05	CbGpPWpGaD
Naphazoline—ADRA2A—GPCR downstream signaling—PIK3CA—coronary artery disease	8.38e-06	4.02e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—SERPINE1—coronary artery disease	8.37e-06	4.01e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—JAK2—coronary artery disease	8.36e-06	4.01e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CASP3—coronary artery disease	8.35e-06	4e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—IL6—coronary artery disease	8.3e-06	3.98e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—AKT1—coronary artery disease	8.2e-06	3.93e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—PIK3CA—coronary artery disease	8.19e-06	3.93e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CCND1—coronary artery disease	8.13e-06	3.9e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—FGF2—coronary artery disease	8.1e-06	3.88e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—NOS3—coronary artery disease	7.99e-06	3.83e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MMP9—coronary artery disease	7.89e-06	3.78e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—JAK2—coronary artery disease	7.77e-06	3.72e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—AKT1—coronary artery disease	7.66e-06	3.67e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CXCL8—coronary artery disease	7.63e-06	3.66e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—PIK3CA—coronary artery disease	7.61e-06	3.65e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—VEGFA—coronary artery disease	7.59e-06	3.64e-05	CbGpPWpGaD
Naphazoline—ADRA1A—GPCR downstream signaling—AKT1—coronary artery disease	7.37e-06	3.53e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CASP3—coronary artery disease	7.3e-06	3.5e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—IL6—coronary artery disease	7.26e-06	3.48e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CCND1—coronary artery disease	7.11e-06	3.41e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CXCL8—coronary artery disease	7.09e-06	3.4e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—VEGFA—coronary artery disease	7.09e-06	3.4e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—TGFB1—coronary artery disease	6.97e-06	3.34e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MMP9—coronary artery disease	6.9e-06	3.31e-05	CbGpPWpGaD
Naphazoline—ADRA2A—GPCR downstream signaling—AKT1—coronary artery disease	6.85e-06	3.28e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MAPK1—coronary artery disease	6.83e-06	3.27e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CASP3—coronary artery disease	6.79e-06	3.25e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—IL6—coronary artery disease	6.74e-06	3.23e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—AKT1—coronary artery disease	6.69e-06	3.21e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PIK3CA—coronary artery disease	6.62e-06	3.17e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CCND1—coronary artery disease	6.6e-06	3.16e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—TGFB1—coronary artery disease	6.51e-06	3.12e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MMP9—coronary artery disease	6.41e-06	3.07e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MAPK1—coronary artery disease	6.38e-06	3.06e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—AKT1—coronary artery disease	6.22e-06	2.98e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—VEGFA—coronary artery disease	6.2e-06	2.97e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PIK3CA—coronary artery disease	5.93e-06	2.84e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—VEGFA—coronary artery disease	5.76e-06	2.76e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—TGFB1—coronary artery disease	5.69e-06	2.73e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MAPK1—coronary artery disease	5.58e-06	2.67e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PIK3CA—coronary artery disease	5.54e-06	2.65e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—AKT1—coronary artery disease	5.41e-06	2.59e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PIK3CA—coronary artery disease	5.38e-06	2.58e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—TGFB1—coronary artery disease	5.28e-06	2.53e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—IL6—coronary artery disease	5.25e-06	2.51e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MAPK1—coronary artery disease	5.18e-06	2.48e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—IL6—coronary artery disease	4.9e-06	2.35e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—AKT1—coronary artery disease	4.84e-06	2.32e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PIK3CA—coronary artery disease	4.84e-06	2.32e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—AKT1—coronary artery disease	4.52e-06	2.17e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PIK3CA—coronary artery disease	4.5e-06	2.15e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—AKT1—coronary artery disease	4.39e-06	2.11e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IL6—coronary artery disease	4.29e-06	2.05e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IL6—coronary artery disease	3.98e-06	1.91e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—AKT1—coronary artery disease	3.95e-06	1.89e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—AKT1—coronary artery disease	3.67e-06	1.76e-05	CbGpPWpGaD
